Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…

Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–rearranged
non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease …

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly
improved overall survival (OS) and progression-free survival (PFS) compared with …

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …

Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients
with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy …